Genetics and fluids can guide allocation of mechanism-specific therapies: complement variants (CFH, C3, CFI) for complement targeting in AMD; aqueous/vitreous cytokines (IL-6/IL-8/CCL2) for inflammatory adjuncts in DR; T cell phenotypes and adhesion-molecule signatures to select uveitis biologics or trafficking blockers (76, 77). This evidence concerns the gene CFH and age-related macular degeneration.